VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the European Commission (EC) has granted Marketing Authorisation for PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] for active immunisation against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. It can also be expected that hepatitis D will be prevented by immunisation with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection. The use of PreHevbri should be in accordance with official recommendations. PreHevbri contains the full antigenic composition of the hepatitis B virus surface antigen, including the S, pre-S2, and pre-S1 HBV surface antigens, and is the only approved 3-antigen HBV vaccine for adults in the European Union (EU) and in the European Economic Area (EEA) countries – Iceland, Liechtenstein, and Norway.
“We are excited to be able to announce the approval of PreHevbri in Europe, marking our second major approval for this differentiated HBV vaccine in five months, following the U.S. FDA approval at the end of November last year,” said Jeff Baxter, VBI’s President and CEO. “Hepatitis B is a highly infectious, under-reported, persistent public health problem in Europe and we believe PreHevbri has the potential to be a meaningful new tool for healthcare providers as they endeavor to fight it. We are committed to being part of this fight and are working hard to make PreHevbri available in different European countries as quickly as possible.”
The European Commission’s centralized marketing authorisation is valid in all EU Member States as well as in the European Economic Area (EEA) countries (Iceland, Liechtenstein, and Norway). VBI expects to make PreHevbri available in certain European countries beginning at the end of 2022.
The approval follows a positive opinion granted in February 2022 by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which was based on the positive results from two pivotal, randomized, double-blind, controlled Phase 3 clinical studies, PROTECT and CONSTANT. Data from these studies were published, respectively, in The Lancet Infectious Diseases in May 2021 and The Journal of the American Medical Association Network Open in October 2021. Both studies compared PreHevbri to Engerix-B, a single-antigen HBV vaccine. Results from the PROTECT study showed that PreHevbri elicited higher rates of seroprotection in all subjects age 18+ (91.4% vs. 76.5%), including in adults age 45+ (89.4% vs. 73.1%). The integrated safety analysis of both studies demonstrated good tolerability with no unexpected reactogenicity. The most common adverse events in all age groups were injection site pain and tenderness, myalgia, and fatigue, all which generally resolved without intervention in 1-2 days.
VBI continues to support the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) review as part of the EC Decision Reliance Procedure (ECDRP), which was initiated upon receipt of the positive CHMP opinion in February.
About Hepatitis B
Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma.
VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. It is approved for use in the European Union/European Economic Area, the United States, and Israel. The brand names for this vaccine are : PreHevbri™ (EU/EEA), PreHevbrio™ (US), and Sci-B-Vac® (Israel).
Full European Summary of Product Characteristics for PreHevbri are available from the EMA website at www.ema.europa.eu.
Please visit www.PreHevbrio.com for U.S. Important Safety Information for PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], or please see U.S. Full Prescribing Information.
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel. For more information, visit www.vbivaccines.com.
Cautionary Statement on Forward-looking Information
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to successfully manufacture and commercialize PreHevbrio/PreHevbri; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of pipeline candidates and the commercialization of PreHevbrio/PreHevbri; the ability to obtain appropriate or necessary regulatory approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 7, 2022, and filed with the Canadian security authorities at sedar.com on March 7, 2022, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005250/en/
Director, Corporate Communications & IR
Phone: (617) 830-3031 x124
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SimCorp Unites with FlexTrade to Add New EMS Ecosystem Partner28.3.2023 09:02:00 CEST | Press release
SimCorp, an independent provider of investment management solutions, has partnered with FlexTrade Systems, a global leader in high-performance multi-asset trade execution management systems (EMS), to extend SimCorp's Order Management System (OMS) capabilities by incorporating the cross-asset EMS functionality of FlexTrade's FlexTRADER EMS. This partnership addresses the increasing demand from trading teams for seamless integration and collaborative workflows between their OMS and EMS solutions. The integration will help optimize trading activities and assist in meeting best execution obligations. As part of the partnership, FlexTrade will join SimCorp's Open Platform program. The Open Platform program is designed to offer its client base frictionless access to innovative fintech solutions across the investment value chain. A key component of the new agreement will see the two firms work together to deliver enhanced, seamless connectivity between SimCorp's OMS, Order Manager, and FlexTr
euNetworks Forms Exclusive Partnership on CrossChannel Fibre System to Deliver Ultra-Low Latency Services Between London and Madrid28.3.2023 09:00:00 CEST | Press release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has entered into an exclusive partnership agreement with Crosslake Fibre UK Limited (“Crosslake”), an international network provider and developer of unique subsea and terrestrial fibre networks. This partnership relates to Crosslake’s new CrossChannel Fibre system and gives euNetworks exclusivity to deliver ultra-low latency services between the United Kingdom and Madrid on this system to the financial services community. euNetworks has also agreed to a strategic relationship, enabling the sale of dark fibre services by euNetworks using the system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230328005180/en/ Paula Cogan, CEO of euNetworks (Photo: Business Wire) CrossChannel Fibre is a 550km cable system with end-to-end fibre running between Slough, United Kingdom and Paris, France and is the first subsea
Adva Network Security protects TransnetBW’s communication network28.3.2023 09:00:00 CEST | Press release
Adva Network Security today announced that TransnetBW has deployed its ConnectGuard™ encryption technology with the Adtran FSP 3000 optical transport solution to establish a highly secure communication network in its service area. As the operator of an electricity transmission grid in southwestern Germany and a European interconnection partner, TransnetBW depends on the security and reliability of its communication network to ensure trouble-free operations. That’s why the company chose the FSP 3000 optical platform with Adva Network Security encryption technology, which has been approved by the German Federal Office for Information Security (BSI). This solution enables high-speed connections to be reliably and robustly protected, even against sophisticated cyberattacks. Planning and implementation of the highly secure infrastructure were carried out by Adva Network Security’s long-standing partner Syserso Networks, who will also provide ongoing support. This press release features mult
Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse ® G NfL CSF and Lumipulse ® G NfL Blood tests28.3.2023 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light (NfL) in human Cerebrospinal fluid (CSF) and plasma/serum, respectively, within just 35 minutes. The two assays are available for Research Use Only. “In 2022, we introduced three fully automated blood-based assays for the detection of pTau181, β-Amyloid1-42 and β-Amyloid1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid lineup of tests for the entire neurodegenerative
Sofinnova Partners Launches Digital Medicine Strategy28.3.2023 06:00:00 CEST | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today that it has launched a new investment strategy focused on digital medicine. The strategy will be headed by Partners Edward Kliphuis and Simon Turner, who bring over a decade of experience investing in startups at the intersection of biology, data, and computation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005697/en/ Edward Kliphuis (left) and Simon Turner (right) (Photo: Business Wire) Sofinnova Digital Medicine will back entrepreneurs innovating at the cutting edge of technology and biology and help them scale to become global leaders. Like all the funds on Sofinnova’s platform, Sofinnova Digital Medicine will focus on developing the most promising innovations that address systemic challenges in healthcare and can profoundly improve the lives of patients worldwide. Antoine Pap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom